LLY and GPCR Related Headlines
Go Back- Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
- Bernstein on US Pharma and Biotech: Who might buy whom?
- Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
- Leerink on Structure Therapeutics (GPCR): 'Oral GLP-1 Achieves Best-In-Class Weight Loss'
- RBC: 'Our focus for LLY remains on the pending Orfo approval and subsequent launch'
- Citizens Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
